Protalix Could Swiftly and Efficently Produce Ebola Drug If Necessary

September 8, 2014 | Israeli company Protalix Biotherapeutics experienced a spike in its share price on the TASE after reports that it can synthesize a vaccine to treat Ebola. With the recent outbreak of the deadly virus in Western Africa, and the cure of at least one US aid worker who contracted the virus using a depleting Canadian vaccine, Protalix is hopeful that they will be able to produce a similar drug swiftly and efficiently. However, according to Protalix CEO Dr. David Aviezer, the Protalix drug has no connection to the Canadian vaccine that was used to cure the aid worker, and the latter vaccine is patent protected by the World Health Organization.